Tumor budding and fibrotic focus-proposed grading system for tumor budding in invasive carcinoma no special type of the breast.

Breast cancer Fibrotic focus Tumor budding Tumor cell–stromal cell interaction Tumor stroma

Journal

Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 22 10 2021
accepted: 05 05 2022
revised: 18 04 2022
pubmed: 14 6 2022
medline: 4 8 2022
entrez: 13 6 2022
Statut: ppublish

Résumé

Tumor budding grade is a very useful histological prognostic indicator for colorectal cancer patients. Recently, it has been also reported as a significant prognostic indicator in invasive breast carcinoma patients. Our group and others have previously reported that the presence of a fibrotic focus in the tumor is a very useful histological finding for accurately predicting the prognosis in patients with invasive carcinoma of no special type (ICNST) of the breast. The purpose of the present study was to investigate whether a grading system incorporating tumor budding in a fibrotic focus is superior to the conventional grading system for tumor budding to accurately predict outcomes in patients with ICNST. According to our new grading system, we classified the tumors into grade I (164 cases), grade II (581 cases), and grade III (110 cases), and the results clearly demonstrated the significant superiority of the new grading system over that of conventional tumor budding alone for accurately predicting outcomes in patients with ICNST. Our findings strongly suggest that tumor cells and tumor-stromal cells interaction play very important roles in tumor progression rather than tumor cells alone.

Identifiants

pubmed: 35695928
doi: 10.1007/s00428-022-03337-0
pii: 10.1007/s00428-022-03337-0
pmc: PMC9343319
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

161-190

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s).

Références

J Natl Cancer Inst. 2019 Sep 1;111(9):983-995
pubmed: 30816935
Virchows Arch. 2021 Apr;478(4):719-726
pubmed: 33330964
Mod Pathol. 2020 Sep;33(9):1783-1790
pubmed: 32366941
Histopathology. 2001 Oct;39(4):416-25
pubmed: 11683944
Ann Surg Oncol. 2013 Sep;20(9):2842-9
pubmed: 23539156
Pathol Res Pract. 2013 May;209(5):269-75
pubmed: 23561623
Cancer Res. 2018 Sep 1;78(17):4902-4914
pubmed: 29967264
Br J Cancer. 2018 Jul;119(2):164-169
pubmed: 29755119
Mod Pathol. 2012 Oct;25(10):1397-404
pubmed: 22684218
Jpn J Cancer Res. 1997 Jun;88(6):590-9
pubmed: 9263537
Breast Cancer Res Treat. 2016 Jun;157(2):363-371
pubmed: 27155668
Breast Cancer Res Treat. 2003 Sep;81(2):137-47
pubmed: 14572156
Oncogene. 2020 Mar;39(12):2453-2466
pubmed: 31974473
Eur J Cancer. 2017 Sep;82:219-227
pubmed: 28292559
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
Am J Surg Pathol. 2019 Feb;43(2):229-234
pubmed: 30334831
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Gastroenterology. 2018 Dec;155(6):1999-2013.e3
pubmed: 30165049
Virchows Arch. 2021 Jun;478(6):1071-1078
pubmed: 33398430
Oncol Lett. 2018 Feb;15(2):2431-2440
pubmed: 29434955
Mod Pathol. 2002 May;15(5):502-16
pubmed: 12011255
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Mod Pathol. 2013 Feb;26(2):295-301
pubmed: 23018875
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Eur J Cancer. 2005 Sep;41(14):2093-101
pubmed: 16153819
Breast Cancer Res Treat. 2015 Apr;150(2):363-71
pubmed: 25779101
Mod Pathol. 1999 May;12(5):492-8
pubmed: 10349987
Hum Pathol. 2017 Aug;66:222-229
pubmed: 28655638
Clin Cancer Res. 2008 May 15;14(10):2944-52
pubmed: 18483361
Mod Pathol. 2016 Oct;29(10):1155-64
pubmed: 27363491
Breast Cancer Res Treat. 2018 Apr;168(3):601-612
pubmed: 29273955
Mod Pathol. 2010 May;23(5):662-72
pubmed: 20208478
Mod Pathol. 2017 Sep;30(9):1299-1311
pubmed: 28548122
Virchows Arch. 2015 May;466(5):485-93
pubmed: 25701480
Am J Surg Pathol. 2009 Jan;33(1):134-41
pubmed: 18971777
Virchows Arch. 2021 Jul;479(1):45-55
pubmed: 33404852
Virchows Arch. 2021 Mar;478(3):393-400
pubmed: 32761393
Int J Cancer. 2019 Sep 15;145(6):1570-1584
pubmed: 30834519
Histopathology. 2002 Feb;40(2):127-32
pubmed: 11952856
Breast Cancer Res Treat. 2010 May;121(1):211-8
pubmed: 19280340
Histopathology. 2019 Mar;74(4):536-544
pubmed: 30450728
PeerJ. 2019 Nov 15;7:e8067
pubmed: 31741805
Arch Pathol Lab Med. 2020 Sep 1;144(9):1097-1107
pubmed: 32142367
Int J Cancer. 2020 Apr 15;146(8):2296-2304
pubmed: 31901133

Auteurs

Miyuki Hiratsuka (M)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Takahiro Hasebe (T)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan. thasebe@saitama-med.ac.jp.

Yuki Ichinose (Y)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Ayaka Sakakibara (A)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Akihiro Fujimoto (A)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Noriko Wakui (N)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Satomi Shibasaki (S)

Community Health Science Center, Saitama Medical University, 29, Morohongou, Moroyama Town, Iruma district, Saitama, 350-0495, Japan.

Masataka Hirasaki (M)

Department of Clinical Cancer Genomics, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Masanori Yasuda (M)

Department of Pathology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Akemi Nukui (A)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Hiroko Shimada (H)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Hideki Yokogawa (H)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Kazuo Matsuura (K)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Takashi Hojo (T)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Akihiko Osaki (A)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Toshiaki Saeki (T)

Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, 350-1298, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH